NVAX Stock Price: Novavax surges over 10% to start the week on optimism surrounding coronavirus vaccine trials
Premium|Take advantage of 50% OFF on your first month.
Start your subscription and get access to all our original articles.
You have reached your limit of 5 free articles for this month.
Get Premium without limits for only $9.99 for the first month
Access all our articles, insights, and analysts.
UNLOCK OFFER- NASDAQ:NVAX reported positive phase one trial results and is deep into its phase two trials now.
- Vaccine supply deals with the US, UK, Canada, and South Korea have led to Wall Street Analysts issuing buy ratings for the stock.
Operation Warp Speed and the race for a coronavirus vaccine has been a focal point for the entire world as we approach the first year anniversary of the virus’ initial spread. It has also grabbed the attention of investors who have been trying all year to anticipate which biotech or pharmaceutical company to buy shares of. Novavax (NASDAQ:NVAX) investors have been on a wild ride this year with the 52-week range starting at $3.54 and rising as high as $189.40. The news of rival AstraZeneca (NYSE:AZN) temporarily halting its phase three trials combined with positive results from Novavax’s own trials has caused the stock to spike another 25% over the past week.
Novavax still lags behind some of its competitors like the aforementioned AstraZeneca, as well as Moderna (NASDAQ:MRNA) and Pfizer (NYSE:PFE) who are all either about to start or are into phase three of their respective clinical trials. The Maryland based firm may have to settle for being a supplier of a second wave of vaccines – even though it does already have established contracts to provide vaccines to several countries around the world.
NVAX stock news
Where the stock goes from here is anyone’s guess. The volatility of biotech stocks fluctuates as soon as any positive or negative trial results are issued. One saving grace for Novavax is that it does have other products it is working on that can act as additional revenue streams for the future. NanoFlu, a flu vaccine, is a potential boon for the over 65 population that is hardest hit by seasonal viruses. Novavax will have to prove that its COVID-19 vaccine has the efficacy results to be mentioned alongside the other biotech heavy hitters – if they can, the stock could see another rise up to its previously lofty levels.
- NASDAQ:NVAX reported positive phase one trial results and is deep into its phase two trials now.
- Vaccine supply deals with the US, UK, Canada, and South Korea have led to Wall Street Analysts issuing buy ratings for the stock.
Operation Warp Speed and the race for a coronavirus vaccine has been a focal point for the entire world as we approach the first year anniversary of the virus’ initial spread. It has also grabbed the attention of investors who have been trying all year to anticipate which biotech or pharmaceutical company to buy shares of. Novavax (NASDAQ:NVAX) investors have been on a wild ride this year with the 52-week range starting at $3.54 and rising as high as $189.40. The news of rival AstraZeneca (NYSE:AZN) temporarily halting its phase three trials combined with positive results from Novavax’s own trials has caused the stock to spike another 25% over the past week.
Novavax still lags behind some of its competitors like the aforementioned AstraZeneca, as well as Moderna (NASDAQ:MRNA) and Pfizer (NYSE:PFE) who are all either about to start or are into phase three of their respective clinical trials. The Maryland based firm may have to settle for being a supplier of a second wave of vaccines – even though it does already have established contracts to provide vaccines to several countries around the world.
NVAX stock news
Where the stock goes from here is anyone’s guess. The volatility of biotech stocks fluctuates as soon as any positive or negative trial results are issued. One saving grace for Novavax is that it does have other products it is working on that can act as additional revenue streams for the future. NanoFlu, a flu vaccine, is a potential boon for the over 65 population that is hardest hit by seasonal viruses. Novavax will have to prove that its COVID-19 vaccine has the efficacy results to be mentioned alongside the other biotech heavy hitters – if they can, the stock could see another rise up to its previously lofty levels.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.